Login
$PTCT
$60.97 -$2.52 (3.97%) Live

$PTCT 8-K/A SEC Filings

Filed On Filing
03 Jul 2017 8-K/A: Financial Statements and Exhibits

On April 20, 2017, PTC Therapeutics, Inc. ("PTC" or the “Company”) completed its acquisition of all rights to EMFLAZA™ (deflazacort) (the “Transaction”) pursuant to an asset purchase agreement (the "Asset Purchase Agreement"), dated Marc...

30 Jun 2017 8-K/A: Regulation FD Disclosure

Accessing EMFLAZA™ (deflazacort) for Duchenne muscular Dystrophy PPMD 2017 Connect Conference June 29, 2017; 4:00pm Stuart Peltz, PhD PTC Therapeutics, South Plainfield, NJ

23 Mar 2016 8-K/A: Costs Associated with Exit or Disposal Activities

On March 18, 2016, PTC Therapeutics, Inc. (the “Company”) committed to a reduction in workforce of approximately 18%, which will primarily affect employees and contractors in the U.S. The reduction in workforce is part of the Company’s p...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support